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Abstract
Background:  Clinical depression is common, debilitating and treatable; one in four people
experience it during their lives. The majority of sufferers are treated in primary care and only half
respond well to active treatment. Evidence suggests that folate may be a useful adjunct to
antidepressant treatment: 1) patients with depression often have a functional folate deficiency; 2)
the severity of such deficiency, indicated by elevated homocysteine, correlates with depression
severity, 3) low folate is associated with poor antidepressant response, and 4) folate is required for
the synthesis of neurotransmitters implicated in the pathogenesis and treatment of depression.
Methods/Design:  The primary objective of this trial is to estimate the effect of folate
augmentation in new or continuing treatment of depressive disorder in primary and secondary
care. Secondary objectives are to evaluate the cost-effectiveness of folate augmentation of
antidepressant treatment, investigate how the response to antidepressant treatment depends on
genetic polymorphisms relevant to folate metabolism and antidepressant response, and explore
whether baseline folate status can predict response to antidepressant treatment.
Seven hundred and thirty patients will be recruited from North East Wales, North West Wales
and Swansea. Patients with moderate to severe depression will be referred to the trial by their GP
or Psychiatrist. If patients consent they will be assessed for eligibility and baseline measures will be
undertaken.
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Blood samples will be taken to exclude patients with folate and B12 deficiency. Some of the blood
taken will be used to measure homocysteine levels and for genetic analysis (with additional
consent). Eligible participants will be randomised to receive 5 mg of folic acid or placebo. Patients
with B12 deficiency or folate deficiency will be given appropriate treatment and will be monitored
in the 'comprehensive cohort study'. Assessments will be at screening, randomisation and 3
subsequent follow-ups.
Discussion: If folic acid is shown to improve the efficacy of antidepressants, then it will provide a
safe, simple and cheap way of improving the treatment of depression in primary and secondary
care.
Trial registration: Current controlled trials ISRCTN37558856
Background
Clinical depression is common, debilitating and treatable;
one in four people experience it during their lives. By
2020, unipolar major depression is predicted to be the
second leading cause of disability worldwide [1].
Impaired physical, social and occupational functioning
are characteristic of depression, as is increased mortality
via suicide, alcohol and drug misuse, and increased rates
of cardiovascular disease [2]. Depression thus burdens
individuals, families, the NHS, and the national economy
[3]. Sub-optimal treatment of depressive disorders is
therefore of great public health concern. Mental health is,
like cardiovascular disease, the subject of a National Serv-
ice Framework and thus reflects the priority given to the
recognition and management of depression.
Despite a striking increase in the number of antidepres-
sant options over the last 50 years their effectiveness
remains largely unchanged. In line with National Institute
of Clinical Excellence (NICE) guidance [4] the great
majority of recognised sufferers are treated in primary
care. However only half respond well to active treatment,
while one-third respond to placebo [5]. According to
NICE guidelines [4] selective serotonin reuptake inhibi-
tors (SSRIs) are as effective in outpatient depression as tri-
cyclic antidepressants (TCAs); since SSRIs generally have
fewer side effects, they are recommended as first-line treat-
ment in primary care.
The monoamine hypothesis of depression implicates a
functional deficiency of noradrenaline (NA) or serotonin
(5-hydroxytryptamine, 5-HT) in neurotransmission; vir-
tually all antidepressants are thought to act by prolonging
the activity of these neurotransmitters or by modulating
receptor sensitivity [6]. Folate is an essential cofactor for
the biosynthesis of both 5-HT and NA. Thus folate defi-
ciency leads to impaired 5-HT synthesis in the human
brain [7]. Moreover, studies demonstrate that up to one-
third of patients with depressive illness have decreased
plasma and red cell folate levels [8]. This may result from
poor nutrition or socio-economic disadvantage, both
common in chronic mental illness. Patients with low
folate respond less well to antidepressant therapy [9].
However, current clinical measures of folate status do not
detect patients who may have functional rather than abso-
lute deficiency.
Homocysteine, a toxic amino-acid metabolite elevated in
functional folate deficiency, is a highly sensitive marker of
folate status. A recent cohort study demonstrated that
hyperhomocysteinaemia (plasma level >15 μmol/L), but
not total serum folate or vitamin B12, is significantly
related to depression severity (odds ratio = 1.90; 95% con-
fidence interval = 1.11–3.25)[10]. Another study that
examined 412 people aged between 60 and 64 years
found that low folate and high homocysteine, but not low
vitamin B12 levels, are correlated with depressive symp-
toms [11]. Further evidence of a possible role of impaired
folate metabolism in depression is suggested by a finding
that patients homozygous for an abnormal variant of the
methylenetetrahydrofolate reductase gene experience
more severe depression (odds ratio = 1.69; 95% confi-
dence interval = 1.09–2.62)[12]. This study has not been
replicated, however, and was associated with a relatively
modest odds ratio, less than expected with homocysteine.
The use of genotyping to predict the effectiveness of folate
supplementation of antidepressants thus needs further
critical examination in appropriately powered studies that
also take into account functional measures such as homo-
cysteine level. Such a strategy should also acknowledge
that folate metabolism in the human body is extraordi-
narily complex; 27 enzymes are involved, many of which
exhibit polymorphisms [13].
A variety of evidence thus suggests that folate may be a
useful adjunct to antidepressant treatment: 1) patients
with depression often have a functional folate deficiency;
2) the severity of such deficiency, indicated by elevated
homocysteine, correlates with depression severity, 3) low
folate is associated with poor antidepressant response,
and 4) folate is required for the synthesis of neurotrans-
mitters implicated in the pathogenesis and treatment ofBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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depression. Despite such suggestive evidence few attempts
have been made to determine the effect of folic acid sup-
plementation on drug treatment of depression. A
Cochrane systematic review and meta-analysis identified
only two randomised controlled trials (combined n =
151) examining the role of folate augmentation in depres-
sion [14,15]. The trials differed substantially in recruit-
ment criteria and provide little evidence for or against the
routine use of folic acid in antidepressant treatment. In
only one of the studies was folate given in its dietary form,
in this case combined with fluoxetine [16]. Folic acid at
only 0.5 mg per day was adequate to change serum homo-
cysteine status, and to enhance antidepressant action, in
females but not males. Thus the differential effect in men
and women may have been due to the low dose of folic
acid used in the study. In addition, abnormal clinical
chemistry, (e.g. raised mean corpuscular volume as seen
in folate deficiency) was used to exclude patients. The
other study utilised a higher dose of methylfolate (15 mg)
and selected patients with low red cell folate (<200 μg/L)
but was of low power, with only 24 patients [17]. No
study to date has used pharmacological doses of folic acid
(i.e., 5 mg daily) to augment pragmatic antidepressant
therapy. Hence there is a clear need for a trial with suffi-
cient power to examine the effect of folic acid supplemen-
tation in the treatment of clinical depression. The effects
of folic acid supplementation may vary across different
clinical populations encountered in primary and second-
ary care; in particular, the clinical and cost effectiveness of
folate augmentation for new cases may differ from that of
cases with continuing but ineffective antidepressant pre-
scription. In addition, the biological mechanism of folate
augmentation may differ across different antidepressant
treatments; accordingly, a comparison of SSRI versus
other antidepressants is of interest.
The evidence, reviewed above, suggests that folic acid sup-
plementation may augment antidepressant response. This
is consistent with the finding that baseline levels of folate
within the normal range predict antidepressant response
[18]. In addition, there is evidence to suggest that folate
deficiency, (e.g., as may be produced by inflammatory dis-
orders or anticonvulsant drug treatment [19]), may aggra-
vate depression or impair response to treatment.
Since dose-response relationship for folic acid as an
adjunct to antidepressant treatment is not known, it is
necessary to consider other evidence with regard to appro-
priate dose choices for use with antidepressant. Based on
known pharmacology of folate, including its penetration
into the central nervous system and effects on neurotrans-
mitter metabolism, there is little chance that 5 mg would
be less effective than lower dose (e.g., 0.5 mg/day) folic
acid, whereas it could well be more effective. This argu-
ment is bolstered by findings [20,21] that 5 mg/day is
more effective than 0.4 mg/day with respect to both clini-
cal and pre-clinical outcomes in the human cardiovascu-
lar system. There is little available information regarding
the mechanism that may underlie a possible antidepres-
sant-adjuvant effect, although suppression of homo-
cysteine (Hcy) and clinical improvement were both more
common in women than men treated with fluoxetine
combined with folic acid [16]. This result suggests that
higher doses of folic acid may be more effective, especially
in men. Further evidence regarding potential mechanisms
may be inferred from cardiovascular data. In this system
there is growing evidence that Hcy elevation is a marker of
functional folate deficiency, but suppression of Hcy by
folic acid does not correlate with the latter's beneficial
effects. For example, 0.4 mg/day folic acid is adequate to
suppress elevated Hcy, but not to restore disturbed
endothelial function measured using the technique of
flow mediated dilatation of human forearm artery [22].
Furthermore, despite high doses (5 mg) of folic acid being
substantially above the FDA's recommended daily dose
(0.4 mg), there are few risks associated with such high
doses other than for those with B12 deficiency, epilepsy or
malignant disease. Even with lower doses of folic acid,
consultant haematologists advise that vitamin B12 screen-
ing, and exclusion of those found deficient, would be
required. With the exception of patients with malignant
disease and some patients with epilepsy, high dose folate
is known to be safe in various clinical populations, includ-
ing pregnant women and the elderly, provided B12 defi-
ciency is screened and excluded [23]. Thus providing
those patients with contraindicated conditions or treat-
ments are excluded there is no experimental or clinical
disadvantage to using 5 mg/day folic acid dose.
Thus consideration of the appropriate folic acid dose for
trial participants with normal baseline serum folate is lim-
ited by the lack of prior trials of folate augmentation of
antidepressant treatment with essentially no information
available on the nature of the dose-response relationship
apart from the observation that women appear to respond
better than men to low dose (0.5 mg/day) folic acid aug-
mentation of fluoxetine [16]. Accordingly, the decision
regarding folic acid dose depends on considerations of
safety and possible effectiveness of various doses, ranging
from 0.4 mg/day (as is used routinely pre-conception and
in early pregnancy) to 5 mg/day (as is used routinely to
treat folate deficiency). Of the two available tablet doses,
we chose a pharmacological dose of 5 mg/day to improve
our chances of detecting an effect of folate supplementa-
tion in depression.
Methods/Design
The primary objective of this trial is to estimate the effect
of folate augmentation in new or continuing treatment ofBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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depressive disorder in primary and secondary care. Sec-
ondary objectives are to evaluate the cost-effectiveness of
folate augmentation of antidepressant treatment, investi-
gate how the response to antidepressant treatment
depends on genetic polymorphisms relevant to folate
metabolism and antidepressant response, and explore
whether baseline folate status can predict response to anti-
depressant treatment.
This is a multi-centred double blind, placebo-controlled,
randomised trial of folic acid augmentation of pragmatic
antidepressant treatment of moderate-to-severe depres-
sion. The trial investigates the effect of folic acid augmen-
tation on new and continuing antidepressant treatment
over 3 months. Assessments will be at week -2 (baseline 1
– antidepressant initiation if required), week -1 (tele-
phone contact for tolerability of antidepressant), week 0
(baseline 2 – randomisation to folate or placebo), and
weeks 4, 12 and month 6 (outcome measures). Figure 1
shows the flow diagram of the trial.
Outcome measures
To estimate the effectiveness of folic acid in augmenting
antidepressant treatment the trial will measure changes in
depressive symptoms both from the participant's own
experience and from the clinical perspective. The primary
outcome measure is symptom severity as estimated by the
self-rated Beck Depression Inventory (BDI). Clinician-
rated Montgomery-Asberg Depression Rating Scale
(MADRS) and the clinical global impression (CGI) of
change will also measure symptom severity as secondary
measures. Secondary outcome measures will include:
health status (mental and physical aspects of quality of
life) through the SF-12; recording and appropriately
reporting of adverse events (e.g. psychiatric inpatient
admission, attempted or completed suicide, and other
mortality); and side effects as measured by the UKU side
effects scale [24]. Cost-utility analysis will use the Euro-
QoL (EQ-5D), a self complete resource use instrument
and relevant medication history from GPs.
Blood samples at baseline and each follow-up will meas-
ure folate and B12 status. Homocysteine levels will be
determined from blood samples taken at baseline, week
12 and month 6. Pharmacogenetic analysis will be carried
out on blood samples obtained at baseline only.
Compliance will be measured using the following four
methods:
(1) The number of tablets remaining at each follow up
will give a crude estimate of maximum compliance.
(2) Dispensing records for folic acid (or placebo) will be
reviewed to measure persistence with therapy; and dates
on antidepressant medication containers to indicate delay
in collecting repeat prescriptions.
(3) Patients will be asked to complete the Morisky ques-
tionnaire [25], a validated tool for assessing compliance
with tricyclic antidepressants [26] at the 12-week visit
only.
(4) Red cell folate and homocysteine levels will be used as
biochemical measures of compliance.
Referral and recruitment
Patients will be recruited from primary and secondary care
in three NHS Trusts areas – North East Wales, North West
Wales and Swansea, covering a population of about
800,000. A feasibility study in North West Wales estab-
lished two ways of improving the recruitment of patients
from primary care into antidepressant trials: (a) research-
ers visited general practices to register, consent, randomise
and follow-up patients; and (b) responsibility for pre-
scribing shifted from general practitioners to trial psychi-
Flow diagram of trial Figure 1
Flow diagram of trial.
 
Randomisation 
appointment 
1. Treat as usual & count 
2.  Refer back to GP & count 
No 
Screening 
interview  
Yes
GP 
appointment 
No 
No 
Yes 
Patients with depression who either need 1
st prescription, change or optimisation of 
antidepressant treatment, or are not responding well to current antidepressant treatment 
are identified as suitable for trial 
Yes 
No  Does patient 
meet inclusion 
criteria? 
 
Exclude
2 
 
No 
Does the patient 
consent? 
 
Exclude
2 
 
Blood & first baseline measures taken by researcher 
Randomisation appointment made within 2 weeks  
Yes 
Does patient meet 
locally agreed B12 
deficiency criterion? 
B12 treatment 
and second 
baseline 
measures taken 
Does patient meet 
locally agreed folate 
deficiency criterion? 
Treat for folate 
deficiency and 
second baseline 
measures taken 
RANDOMISATION stratified by centre, sex, 
new or continuing antidepressant, 
antidepressant type and counselling 
Second baseline measures taken 
Receive placebo  Receive folate 
Repeat outcome measures at follow-ups  
•  1 (4 weeks post randomisation appointment) 
•  2 (12 weeks post randomisation appointment) 
•  3 (6 months post randomisation appointment) 
 
Exclude
1 
Yes
GP or psychiatrist refers patient to trial via fax /email and provides an information sheet 
Psychiatrist and researcher clarifies trial process, answers questions, assesses eligibility 
and obtains consent  
Is patient willing 
to be screened? 
Trial 
phase 
Trial psychiatrist screens for depression, confirms patient meets ICD-10 criteria for 
moderate to severe depression, & takes appropriate clinical action. If necessary an 
antidepressant will be prescribed, changed or optimised 
Researcher telephones patient to arrange screening appointment 
Trial 
referral 
process 
YesBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
Page 5 of 19
(page number not for citation purposes)
atrists. As a result the study recruited 155 patients in 18
months at a single centre with fewer resources than pro-
posed for FolATED. Where appropriate this study will
adopt a similar model in order to reach our recruitment
target. In addition to minimising the barriers to recruit-
ment we have developed two further strategies. First, GPs
will be reimbursed for the administration costs for each
patient recruited into the trial and second, patients will
complete a depression rating scales (BDI, HADS or
PHQ9) in accordance with GP preferences. These strate-
gies will ensure the proposed sample size is achievable.
Research interested general practices will be identified in
each of the three Trust areas, from the All-Wales Primary
Care Research Database managed by the North Wales
Department of General Practice. Inviting general practices
with a proven interest in research to refer patients to the
study can be an effective way of enhancing recruitment
rates. The feasibility study in North West Wales demon-
strated that research interested practices can recruit up to
20 patients each over a 2-year recruitment period. Thus
365 patients will be recruited from primary care.
The remaining 365 patients will be recruited from second-
ary care. Although most cases of depression are managed
in primary care across Wales, additional diagnostic and
management support is available in somewhat different
configurations in the three target regions. At North East
Wales NHS Trust, patients with common mental health
problems unable to be managed by the GP are referred to
the First Access Mental Health Service; by contrast only
patients with severe and enduring mental illness are
referred to the Community Mental Health Teams
(CMHTs). At North West Wales NHS Trust, patients with
depression requiring referral are directed either to the
practice counsellor, to research projects (e.g. the feasibility
study previously mentioned), or to the local CMHT. Sim-
ilarly, at Swansea NHS Trust patients with depression not
managed effectively in primary care are seen by liaison
psychiatric nurses and may be referred to the Psychiatrist
within the local CMHT.
The Consultant Psychiatrists at each centre will ensure
that their respective teams recruit 122 patients over the
18-month recruitment period, giving a total of 366
patients recruited from secondary care. It is anticipated
that patients recruited from secondary care will predomi-
nantly be continuing cases that have already been initi-
ated on antidepressant treatment. To maximise
recruitment the study will be adopted by the Mental
Health Research Network Cymru (MHRN-Cymru).
Participating GPs will identify patients with depression
and will give them a study booklet if they are interested in
entering the trial. The study booklet will contain details of
the trial in the patient information leaflet and consent
form. Patients willing to be screened will be referred to the
trial using a standardised referral form which will be faxed
to the regional research team. In addition to the patients'
demographic details, the form will also ask the GPs to
note their first and second choice antidepressant in each
instance if they have not been prescribed an antidepres-
sant. Patients not responding adequately to existing anti-
depressant treatment will also be referred to the trial in a
similar manner. Patients with moderate or severe depres-
sion routinely referred to secondary care will also be
recruited into the trial using the same referral process. The
local research professional will contact referred patients
within three days to discuss the study, answer any ques-
tions and to arrange an appointment for a screening inter-
view at the GP surgery or local research centre. Patients
who do not wish to be screened or are ineligible for other
reasons will be offered usual treatment by the GP. To
avoid withholding treatment an appointment will be
made within three working days for new patients who
have yet to be prescribed an antidepressant. For patients
already prescribed an antidepressant an appointment will
be made as soon as possible.
Screening
At the screening interview the Psychiatrist explains what
will happen and will ask the patient if they are happy to
be assessed. Patients will be assessed for depression by the
psychiatrist and asked to complete the BDI as part of the
screening process. (If the GP requests HADS or PHQ9
patients will be asked to complete them in addition to the
BDI.)
The Psychiatrist will take an appropriate clinical action
based on the patients needs such as prescribing or opti-
mising an antidepressant, or onward referral. If the patient
meets ICD-10 criteria for moderate to severe depression
the Psychiatrist will ask the patient if they are willing to be
screened for eligibility. See planned inclusion and exclu-
sion criteria.
Inclusion and exclusion criteria
Inclusion
Only patients aged 18 or over with an ICD-10 diagnosis of
moderate to severe depression [confirmed by the trial psy-
chiatrists during the screening interview using BDI] will
be included. Only patients able to give informed consent
(not delirious, actively psychotic or with severe communi-
cation or learning disability) and able to complete the
research assessments will be included.
Exclusion
Patients will be excluded from the trial if they:BMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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(a) are folate deficient: they cannot be randomised
because they need to be treated with folic acid but can be
included in the comprehensive cohort
(b) are B12 deficient: they cannot be randomised because
they need to be treated with B12 injections but can be
included in the comprehensive cohort
(c) have knowingly taken supplements containing folic
acid within 2 months because this will mask any effects of
folic acid given during the study
(d) suffer from psychosis because additional treatment for
psychosis may mask any benefit of folic acid with antide-
pressants. Plus people suffering from psychosis are less
able to give informed consent and will require referral
through to secondary services.
(e) are already participating in another research project
(f) are pregnant or planning to become pregnant as it is
important for pregnant women to take folic acid so they
cannot be randomised to placebo
(g) are taking anticonvulsants as in very rare circum-
stances folic acid can react with certain anticonvulsants
(h) serious, advanced or terminal illness with a life expect-
ancy of less than 1 year
(i) have recently started treatment for a medical condition
which has not yet been stabilised
(j) are taking lithium
(k) have had a diagnosis or treatment for any malignant
disease or any related condition such as intestinal polypo-
sis
Informed consent
Once eligibility is determined the research professional
and psychiatrist will provide information about the trial
and the patient will be given the opportunity to ask any
question regarding the trial. The patient is told that they
can withdraw from the study at any time without their
usual care being affected. The research team will check
that the patient understands all aspects of the trial includ-
ing the genetics part. The psychiatrist must be happy that
the patient is willing to consent to the trial. Patients will
then be asked to give informed consent to participate in
the trial. If the patient agrees to enter the trial, the patient
must complete two copies of the consent form indicating
which parts of the study they are consenting to. Once the
patient has completed the consent form the Psychiatrist
must sign and date it. One copy of the study booklet with
completed consent form will be given to the patient and
one copy will be kept by the research team. Patients who
do not wish to enter the trial will be referred back to their
GPs.
Baseline measures and blood samples
First baseline measures will be undertaken during this
screening appointment. For new cases of depression, the
GPs can initiate according to their usual practice or they
can refer the patients to the study and the trial psychia-
trists can initiate treatment. To be pragmatic, prescriptions
will take account of preferences expressed by GPs. Where
the GP does not state a preference one of two available
generic SSRIs, namely citalopram or fluoxetine, will be
prescribed. SSRIs will be prescribed according to NICE rec-
ommendations. For depression not responding ade-
quately to treatment, the trial psychiatrist will continue
with the current prescription where appropriate and
adjust dosage in accordance with the current British
National Formulary [27]. If optimisation is required,
patients will be given an optimal dose for 4 weeks before
randomisation.
Note that two key exclusion criteria, namely B12 or folate
deficiency, will be determined via a blood test. For this
reason, blood samples will be taken at the screening inter-
view to determine eligibility in the first instance.
Blood samples (40 ml in total) will be split into three, col-
lected in EDTA tubes (plus a serum gel tube for haematol-
ogy):
(1) Routine haematology. Full blood count, red cell
folate, serum folate and B12, to be analysed in local NHS
laboratories in Bangor, Wrexham and Swansea.
(2) Homocysteine. Samples will be centrifuged within 1
hour and plasma taken off red cells. The resulting plasma
will be stored at -20°C and sent batch-wise to the Univer-
sity Hospital of Wales, Cardiff.
(3) Genetic analysis (if consent is given). Samples will be
sent, as and when taken, to the University of Liverpool.
A further research appointment will be arranged between
the research professional and the patient within 14 days,
in which time the folate and B12 results will be con-
firmed. A copy of the results will be sent to the patient's
GP, again using a standardised form.
Patients who are ineligible or who do not consent to par-
ticipate in the trial will be referred back to their GP for
usual care. When needed an antidepressant will be pre-
scribed to avoid further delays in treatment and anyBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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appropriate clinical action will be taken. A standardised
form will be used for referrals back to GPs.
Blood results and randomisation
Upon receipt of the blood results, the research profession-
als will liaise with the trial psychiatrist to determine B12
and folate status based on locally determined values. The
psychiatrist will then prescribe the appropriate action to
be taken at the second appointment between the research
professional and the participant. At this appointment the
research professionals will inform the participant of their
blood test results and their eligibility to continue in the
trial. Patients whose blood results show B12 deficiency
will be referred back to their GP for immediate treatment
with B12 injections. GPs will be informed of the defi-
ciency with a copy of the blood results. Those patients will
be excluded from the principal trial but will continue in
the 'comprehensive cohort study' of recruited patients.
Thus antidepressant response will be monitored at each
follow-up.
Patients whose serum folate results suggest folate defi-
ciency will have their red cell folate levels reviewed to con-
firm the deficiency. If red cell folate is also below the
normal range for the local laboratory, then we shall
exclude the participant from the trial, but include him or
her in the 'comprehensive cohort study' for follow-up dur-
ing (unblinded) folate supplementation. We shall then
inform the GPs of the required treatment with copies of
the blood results and continue to monitor treatment
responses at each follow-up.
Randomisation, stratification and blinding
Following baseline observations, patients with B12 and
folate levels within the normal range will be randomised
and allocated to folic acid or matching placebo. Partici-
pants will thus receive either a folic acid or placebo
adjunct to their antidepressant treatment. Randomisation
to FoLATED will be achieved by telephone to the remote
randomisation centre at North Wales Organisation for
Randomised Trials in Health (NWORTH) at Bangor Uni-
versity. The randomisation will be performed by dynamic
allocation to protect against subversion while ensuring
that each arm of the trial is balanced for the stratification
variables. Participants will be stratified by (1) centre
(Swansea/Wrexham/Bangor); (2) sex (male/female); (3)
patient type [new/continuing (i.e. having taken the same
daily antidepressant for at least two months with a stable
dose in the therapeutic range (BNF) for at least one
month)] (4) the type of antidepressant prescribed (SSRI/
other) and (5) whether or not they have ever received
counselling for depression.
For validation purposes, additional information is also
requested including the participant's trial number, date of
birth, and the name of the person requesting the randomi-
sation. The following questions will be asked during the
randomisation process:
1. Has consent been given?
2. Does the patient meet ICD10 criteria?
3. Is the patient B12 deficient?
4. Is the patient folate deficient?
If a person requesting the randomisation responds 'Yes' to
the first two questions and then 'No' to the second two
questions the participant can be randomised.
Identically packaged folic acid and placebo will be coded
randomly for each stratification group by NWORTH. Both
folic acid and placebo tablets will appear identical. In this
way the patient, doctor, researchers and pharmacists will
be blind to the intervention. The research professionals at
each centre will hold the trial drugs and distribute as nec-
essary. Each patient's prescription will indicate his or her
trial number and package serial number in addition to the
randomisation code generated by NWORTH. This will
determine the appropriate trial package to be dispensed.
The allocated codes will be recorded in the research notes
and the patient's clinical record. The key to the randomi-
sation code will be held centrally by NWORTH and by the
local pharmacies. A telephone number of the local phar-
macy will also be available so that the code can be broken
in an emergency.
Follow-Ups
There are clinical and methodological reasons for follow-
ing up after 4 weeks, 12 weeks and 6 months. Evidence
suggests that all antidepressants show a delayed and vari-
able onset of clinical improvements in depression [28-
30]. Although some antidepressants reportedly produce
significant improvements within the first week, this typi-
cally continues over subsequent weeks; variability in
response measures also affects the reported timing of
onset of response [28,29]. Available evidence indicates
that around half of eventual responders (judged in week
8) to fluoxetine treatment started to respond within two
weeks and that 75% started to respond within four weeks.
A lack of response within four or six weeks was associated
with 75% or 88% chance respectively of non-response
within eight weeks. However no predictors of response
timing were found. Thus the onset of antidepressant
response, if any, will most likely have occurred by week 6.
We therefore propose to undertake the first outcome
measures follow-up at week 4 (6 weeks after initiation of
antidepressant treatment, or optimisation for continuing
patients) to ensure sufficient time for likely treatmentBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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effects whilst retaining sensitivity to clinical change. In
addition non-response at this point allows for possible
changes to the antidepressant treatment in accordance
with the British National Formulary and NICE guidelines
as stipulated below. Given this early follow-up, we pro-
pose to undertake later follow-up at 12 weeks to measure
late and continued responses to antidepressant treatment.
It is important to monitor relapse rates during the main-
tenance phase of treatment and to identify any effects of
folate on late responders to antidepressants. Evidence sug-
gests that SSRIs are associated with higher rates of relapse
(tachyphylaxis) than other antidepressant classes includ-
ing tricyclic antidepressants (TCAs) and selective
noradrenaline reuptake inhibitors (SNRIs) [31]. Thus fol-
low-up at 12 weeks monitors, not only the effects of folic
acid on clinical outcomes, but also its effect on relapse
rates.
For new patients or continuing patients undertaking opti-
misation, additional telephone follow-ups in week -1 will
gauge tolerability of treatment and suicidality. Where nec-
essary, changes to antidepressant type or dose will be
made. These changes will be the subject of regular sum-
mary reports to the trial Data Monitoring and Ethics Com-
mittee (DMEC).
There are two methodological reasons for follow-up after
4 weeks, 12 weeks and 6 months. First, one of these is dur-
ing treatment with folate, one and the end of treatment
and the final one after some time has lapsed post treat-
ment. Second, the combination of short-, medium- and
long-term measures yields better estimates of the cost-
effectiveness of treatment.
With consent, serum folate, homocysteine and B12 levels
will be assessed at week 12 and at the final follow-up. A
summary of the baseline and follow-up assessments can
be seen in Table 1.
Withdrawal
A participant can withdraw or can be withdrawn from the
treatment. Participants who withdraw from the trial treat-
ment will be asked to attend all the follow-up appoint-
ments. Local research co-ordinators will notify the trial co-
ordinator in writing about all trial participants who wish
to withdraw from all future follow-ups.
Pharmacogenetics Study
There is increasing realisation of the potential importance
of pharmacogenetics in maximising the benefits of medi-
cines and to this end, most commercial trials and an
increasing number of non-commercial trials, now contain
a pharmacogenetic arm. For this reason, a major strand of
this trial is to characterise the role of genetically deter-
mined variation in folate metabolism in clinical outcome.
Prior to the completion of the human genome project, the
conventional strategy utilised for pharmacogenetics
involved the analysis of single variants in single genes.
This has been practiced since the 1960s and unfortunately
has not led to major breakthroughs. Indeed the literature
is littered with contradictory data on pharmacogenetics,
which has made it impossible to translate any benefits
into clinical practice. As stated earlier, folate metabolism
is complex involving 27 different enzymes [13]. The com-
plexity is exacerbated by the fact that folate requires active
transport into cells, and the facilitated transporters show
genetic polymorphisms [32]. To date, only the common
functional genetic polymorphism (C677T) in methylene-
tetrahydrofolate reductase (MTHFR) gene has been
related to depression [12], although no study has yet
related the occurrence of this polymorphism to the effec-
tiveness of folate treatment. No other genes in the folate
pathway have been investigated either in relation to the
severity of depression, response to antidepressant treat-
ment, or to folate supplementation.
Concentrating on just one gene (for example MTHFR, the
most widely studied gene in the folate pathway) would be
unnecessarily restrictive and would ignore the variance in
the other pathways. On the other hand, in the timescale
available in this study, it would not be possible to under-
take an analysis of all 27 genes involved in folate metabo-
lism because (a) the genetic variability has not been
adequately characterised, (b) the functional effects of all
genetic polymorphisms has not been investigated, and (c)
the study has not been powered to look at this number of
genes with an insufficient sample size.
Furthermore, this would also be prohibitively expensive at
this stage. A practical strategy has been adopted, as fol-
lows:
(a) analysis of the most important pathways based on pre-
vious studies in other diseases areas, for example response
to methotrexate;
(b) we will adopt a genetic strategy that involves using tag-
ging SNPs to determine the overall genetic diversity of the
chosen genes. The tagging SNPs will be determined from
the data that are publicly available via the HapMap
project;
(c) we will genotype patient samples for the common pol-
ymorphisms (>10% population frequency) that have
either a known functional effect or can be predicted to
have a functional effect and would therefore be in accord-
ance with the sample size and hence power of the study;
andB
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Table 1: FolATED Baseline and follow-up assessments
Assessment Outcome measure Respondent Trial entry – Baseline Follow-ups
Week -2 
(baseline 1)
Week -1
(Telephone contact)
Week 0 
(baseline 2)
Week 4 Week 12 Month 6
Blood testing Routine haematology
FBC Clinician
Serum folate Clinician
Red Cell folate Clinician
B12 Clinician
Homocysteine Clinician
Genetics Clinician
(needs extra consent)
Depression status BDI Patient
MADRS Clinician/researcher
Health status and quality of life CGI Clinician/researcher
SF-12 Patient
EQ-5D Patient
Health economics Resource usage Patient
Compliance and side effects Morisky Questionnaire Patient
      
UKUside effects scale Clinician/researcher
9
9 9 9
9
9 9 9
9 9 9
9
9 9 9 9
9 9 9 9 9
9 9 9 9 9
9 9 9 9 9
9 9 9 9 9
9 9 9
9
9 9 9 9 9 9BMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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(d) DNA will be stored for future analysis for other vari-
ants in the same and other genes.
This strategy is currently being tested by Prof. Pirmo-
hamed as part of 3 large projects funded through the
Department of Health Pharmacogenetics Initiative. This
strategy will provide the highest chance of identifying
genetic predictors of responsiveness to folate whilst simul-
taneously provide us with a resource, as knowledge of the
genetics of these pathways increases, for future refinement
and identification of other associations.
Thus, although this is a feasible strategy, it will neverthe-
less be the most thorough investigation to date by allow-
ing us to determine critically whether the interaction
between any of the genetic polymorphisms in the folate
pathway predicts the severity of depression, response to
antidepressants per se, and the response to folate supple-
mentation. Furthermore, this will allow us to determine
whether such a strategy has an impact on patient out-
come, and therefore whether it is clinically and cost-effec-
tive in a real-world setting. With this in mind, the
following 7 (out of the possible 27) genes in the folate
pathway will be investigated in the first instance:
￿ methylenetetrahydrofolate reductase
￿ thymidylate synthase
￿ dihydrofolate reductase
￿ methionine synthase
￿ methionine synthase reductase
￿ gamma glutamyl hydrolase
￿ reduced folate carrier (SLC19A1).
The choice of genetic variant within each gene will be
based on (a) literature review of the functionally impor-
tant common polymorphisms; (b) a search of the publicly
available databases including dbSNP http://
www.ncbi.nlm.nih.gov/SNP/; and (c) a search of the Hap-
Map database.
DNA will be extracted according to standard procedure.
Genotyping for polymorphisms will be undertaken using
a medium throughput platform utilising TaqMan technol-
ogy – available in the Department of Pharmacology, Uni-
versity of Liverpool [33]. It is difficult to provide realistic
power calculations in advance since little is known about
the frequency of genetic variants in patients with depres-
sion and the statistical methodology for the analysis of
genetic association studies is still being developed. A key
variable in such studies is the frequency (among cases) of
the SNP minor allele frequency. For rarer variants to be
clinically important, their effect size (measured by the
allelic odds ratio, OR) must be large. We therefore specify
distinct benchmarks for the power analyses: we seek to
have good power for (a) OR = 3 and a variant with a fre-
quency of 10%; (b) OR = 2 for a common variant (>20%).
Note that these effect sizes are for a single causal variant;
we expect to realise much larger effect sizes via combina-
tions of causal variants. The assumed type 1 error is 5%.
Adjustment for multiple testing will be performed by per-
mutation analysis [34]. As indicated above, multiple
regression models will be used to evaluate the importance
of genetic factors in determining clinical outcomes in
patients.
Intervention
Given the increased efficacy of higher folic acid doses in
other body systems and the very low risk of adverse
effects, we have opted for a pharmacological 5 mg/day
folic acid dose or matching placebo to supplement antide-
pressant treatment, the same dose as is routinely used to
treat folate deficiency. This dose is the treatment of choice
for folate deficiency and well tolerated in various clinical
populations, including the elderly and pregnant women
[35,36]. There is no evidence that pharmacological folate
will have a deleterious effect on either methylation status
or mood, nor that it will lead to sub-acute combined
degeneration of the spinal cord or other neurological
complications, provided that B12 deficiency is excluded.
Individuals identified with B12 or folate deficiency will be
excluded from the folate/placebo trial, but will be treated
appropriate and asked to continue to participate in the
'comprehensive cohort study'. People who have been
diagnosed or treated for malignancy will not be able to
receive folic acid. Although there is evidence that high
folate intake lowers the risk of developing cancer if a per-
son has already had a malignant disease there is some evi-
dence that high folate intake may increase cancer growth.
In summary,
￿ 5 mg/day folic acid is safe in working age adults and the
elderly, provided B12 deficiency and diagnosed or treated
malignancy is excluded.
￿ 5 mg/day folic acid is more likely than lower doses to be
effective as an antidepressant adjuvant, based on limited
trial data and folate's known effects in other body systems.
Additional advantages include simplicity, low cost and
ready availability of the 5 mg preparation [27]. The folic
acid dose-response relationship in clinical populations, in
particular those with depression, will need to be deter-
mined in subsequent studies. Patients with folate defi-
ciency continuing in the comprehensive cohort study willBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
Page 11 of 19
(page number not for citation purposes)
be treated with a 5 mg dose of folic acid. Patients with a
B12 deficiency also continuing in the comprehensive
cohort study, will be treated with B12 injections as neces-
sary by the GP. Patients not wishing to continue will be
referred back to their GP for appropriate treatment using
the designated form.
Risks and anticipated benefits for trial participants and 
society, including how the benefits justify the risks
There is suggestive evidence that folate may enhance the
effects of antidepressants for those suffering depression.
Thus patients requiring antidepressant treatment may
benefit from supplementing their treatment with folic
acid. The associated risks with folic acid supplementation
are very low. Folic acid is normally well tolerated but occa-
sionally nausea, allergic reactions, anorexia and abdomi-
nal distension can occur. However, there is a potential risk
for patients with B12, folate deficiency or malignancy.
Those patients with B12 deficiency must not receive folate
and will be excluded from the trial. They will be asked to
continue to participate as part of the 'comprehensive
cohort study' and will be referred back to their GP for
immediate treatment with B12 injections. Similarly,
patients with folate deficiency must be treated with folic
acid and it would be unethical to randomise these
patients to receive placebo. For this reason, they will also
be invited to continue to participate as part of the compre-
hensive cohort in an unblinded folate group and moni-
tored as appropriate.
Patients with mental health problems might be viewed as
a vulnerable population and therefore appropriate meas-
ures will be taken to ensure that they fully understand the
nature of the trial and the risks and benefits of the treat-
ment. We recognise that people suffering from moderate
to severe depression may have reduced capacity to assim-
ilate information and we will thus ensure that all informa-
tion is clear, user friendly, honest, and precise.
Information will be given verbally in addition to written
information sheets and the research professionals will be
available to answer any question. If folic acid augmenta-
tion is shown to be beneficial, it would be a cheap, safe
and simple method of improving treatment of a common,
debilitating illness in primary care.
Informing potential trial participants of possible benefits 
and known risks of the intervention (or of no intervention 
or a placebo)
Information sheets will be given to patients to keep which
will explain in detail all the benefits and risk of participat-
ing in the trial. Research professionals will be available to
answer any questions and respond to any difficulty expe-
rienced during the trial. Patients will be given the oppor-
tunity to nominate an advocate (e.g., family member) if
they wish. Participants will be asked not to take folic acid
supplements (including multivitamin preparations con-
taining folic acid) outside of the trial and any individual
that becomes pregnant during the trial will be asked to
inform the appropriate research professional. These
patients will be followed-up as intention to treat. At each
appointment participants will also be asked if they are tak-
ing any additional supplements.
Safety monitoring and reporting
To ensure that the safety of folic acid is properly moni-
tored and reported this protocol stipulates the definitions
used to identify different types of adverse events (AE) and
the associated reporting requirements (adapted from the
EU Directive [37]). All adverse events will be assessed for
causality, seriousness and expectedness. That is whether
the AE is related to the drug; whether the AE is serious; and
whether the AE was unexpected. Table 2 shows how these
three features apply to the main types of AEs.
Causality
Causality is the degree to which an untoward medical
occurrence can be attributed to the trial drug and can be
classed as either unrelated, unlikely to be related, possibly
related, probably related or definitely related. Only unto-
ward medical occurrences that are considered to be either
possibly, probably or definitely related to the trial drug
will be reported as having a causal relationship.
If the untoward medical occurrence is not considered to
have a causal relationship with the treatment at the time
of the event (i.e. it is not believed to be a consequence of
taking folic acid or placebo) this will be classified as an
Adverse Event. However, if it is considered to have a causal
relationship with folic acid or placebo at the time of the
event it will be classified as an Adverse Reaction.
Seriousness
Any untoward medical occurrence will deemed serious if
it:
￿ results in death
￿ is life-threatening
￿ requires hospitalisation or prolongation of existing hos-
pitalisation
￿ results in persistent or significant disability or incapacity
￿ results in a congenital anomaly or birth defect
Self harm or attempted suicide will also be considered
serious in this study.BMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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All serious events not considered to have a causal relation-
ship with the treatment will be classified and reported as
a Serious Adverse Event (SAE). All serious events that are
considered to have a causal relationship with the treat-
ment will be classified and reported as a Serious Adverse
Reaction (SAR).
Expectedness
An untoward medical occurrence will be considered to be
'unexpected' if its nature and severity are not consistent
with the information in the summary of product charac-
teristics for that treatment. If an adverse event is consid-
ered 1) to be related to the folic acid or placebo 2) is
serious and 3) unexpected then is will be classed as a Sus-
pected Unexpected Serious Adverse Reaction (SUSAR).
Known undesirable effects reported in the summary of
product characteristics include nausea, anorexia, abdomi-
nal distension and allergic reaction.
Responsibility for reporting
The reporting requirements differ depending on the cau-
sality, seriousness and expectedness of the medical occur-
rence as summarised in the flow diagram of safety
reporting (Figure 2).
All adverse events will be recorded on the trial database,
evaluated by the principal investigator or other designated
person responsible for the clinical aspect of the trial in
each centre and included in the annual safety report to the
MREC and MHRA.
However, for all events considered serious additional
reporting is required. The trial co-ordinating centre must
be informed within 24 hours of investigator's knowledge
of the event. A Serious Adverse Event Form must be com-
pleted and sent to the trial co-ordinating centre as soon as
possible. The trial co-ordinator will immediately contact
the clinical and methodological chief investigators who
have been delegated the responsibility of reporting any
serious adverse events on behalf of the sponsor (Bangor
University). A decision must then be made by the investi-
gator with the clinical responsibility for aspects of the
patient's care which are relevant to the trial as to whether
an adverse event is related to folic acid or placebo. The
investigator should decide the degree to which the event
is caused by the trial drug. If a decision cannot be made,
the investigator must contact the co-ordinating centre.
Advice will be sought from the clinical chief investigator
and other clinicians may be asked if a decision cannot be
reached.
If it is decided that the adverse event is a serious adverse
reaction then it must be determined whether the reaction
is expected. If it is unexpected and thus considered a
SUSAR then the SAE form will be completed and reported
to the MHRA and MREC.
For fatal or life-threatening SUSARs the MHRA and MREC
will be notified as soon as possible but no later than 7 cal-
endar days after the sponsor has first knowledge of the
event. In each case relevant follow-up information will be
sought and a report completed as soon as possible. The
follow-up information will be sent to the MHRA and the
MREC within an additional eight calendar days.
Non-fatal and non life-threatening SUSARs will be
reported to the MHRA and the MREC as soon as possible
but no later than 15 calendar days after the sponsor has
first knowledge of the event. Further relevant follow-up
information will be given as soon as possible.
Serious but expected reactions or non-serious adverse
reactions will be recorded in the database and reported in
the usual way.
Statistics
With national collaboration and adoption of the project
by the Mental Health Research Network Cymru, it is esti-
mated that 730 patients from 3 participating centres can
be randomised to folic acid 5 mg daily or placebo over 1
to 2 years. We estimate that 5% will present with B12 defi-
ciency and 10% with folate deficiency at baseline. These
patients will not enter the main trial but will be treated
appropriately and followed-up as part of the comprehen-
sive cohort. Although up to 33% of patients with depres-
sive illness have decreased plasma and red cell folate
levels [8], not all will be considered folate deficient.
Table 2: Types of adverse events
Adverse 
Events (AE)
Adverse 
Reactions (AR)
Serious Adverse 
Events (SAE)
Serious Adverse 
Reactions (SAR)
Suspected Unexpected 
Serious Adverse 
Reactions (SUSAR)
Is the medical occurrence considered 
to be related to trial drug?
NY N Y Y
Is the medical occurrence serious? N N Y Y Y
Is the medical occurrence unexpected? N N N N YBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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After allowing for 10% loss at each follow-up, and the
exclusion of those with B12 and folate deficiency, a total
of 730 patients recruited would yield 400 participants
completing the trial. We estimate that this would yield
80% power, when using a 5% significance level, to detect
a difference between the folic acid and placebo groups, of
3 points on the Beck Depression Inventory (BDI), gener-
ally considered a meaningful difference (equivalent to an
effect size of 0.3).
Analysis will be by intention to treat. We shall compare
folic acid and placebo using analysis of covariance to take
account of baseline differences, notably in folate levels.
We shall use multi-level modelling to test for heterogene-
ity across sites, and general linear modelling to assess rel-
ative contributions to differences in clinical outcomes.
These include stratification variables (sex, new or contin-
uing patient, and type of anti-depressant); biochemical
variables (especially baseline folate, functional folate defi-
ciency, homocysteine and methylation status); demo-
graphic variables [especially smoking, alcohol and drug
consumption – all known to affect homocysteine levels
[38]]; genetic variables (including interactions with bio-
chemical variables); and pharmacological variables.
Before modelling we shall develop an explicit analysis
plan exploiting previous studies, for example the finding
that baseline folate predicts response to antidepressant
better than homocysteine does [39].
Our pharmaco-economic analysis will evaluate folate aug-
mentation through cost-utility analysis and estimated
cost-effectiveness ratios. Post hoc analysis will also esti-
mate the cost-utility of pharmacogenetic testing, if results
suggest this has predictive value. We shall prospectively
collect major direct costs to the NHS of the health care
resources used by participants. These will include investi-
gations, treatments, use of primary and secondary care
services, trial drug therapy, management of adverse drug
reactions and genotyping. To estimate cost-effectiveness
ratios, we shall estimate treatment effectiveness through
utility scores derived from the EQ-5D. We shall take
account of uncertainty by 'bootstrapping'. We shall iden-
tify potential predictors of response through regression
analysis, and thus analyse the cost-effectiveness of genetic
and biochemical testing post hoc. We shall compare the
estimated incremental cost per QALY of folate augmenta-
tion for new and continuing antidepressant users, and of
laboratory testing, with the results of other economic
assessments of antidepressant treatments.
Economic analysis
We will assess whether the use of folic acid supplementa-
tion is cost-effective by estimating the incremental cost-
utility and cost-effectiveness ratios of antidepressant drug
plus folic acid, relative to antidepressant drug alone. Fur-
ther, a post-hoc analysis will be conducted to estimate the
cost-utility and cost-effectiveness of pharmacogenetic test-
ing, should the trial results suggest that genetic testing is
of predictive value.
Healthcare resource utilisation
We shall use prospective self-complete questionnaires to
assess patients' use of health and social services. These will
be collected by the research professional at baseline, week
4 and week 12 of treatment. The questionnaire will
include items on patients' use of general practice and
community nursing services and social services. We shall
supplement collection of healthcare resource utilisation
data by reviewing patients' GP records after the final 12-
week follow-up. This will allow for the collection of data
on hospital clinic attendance, inpatient admission and
home visits etc.
Cost analysis
The perspective of the NHS will be adopted with the
major direct costs of health care resources used by patients
in the trial being collected prospectively. These will
include treatments and investigations, use of primary and
secondary care clinic services, concomitant and trial drug
Flow diagram of safety reporting Figure 2
Flow diagram of safety reporting.
Is the event assessed as serious? 
All adverse events will be recorded 
and graded by causality and a 
summary of these will be sent to the 
DMEC every 6 months 
No 
Yes 
Is it causally related to the trial 
medication? 
It is a Serious Adverse Event 
Complete the SAE form and report 
to co-ordinating centre within 24 
hours.  SAEs listed in the protocol 
that do not require immediate 
attention should be reported in the 
agreed time frame. 
It is a Serious Adverse Drug Reaction 
Report to co-ordinating centre within 24 
hours CI will assess for expectedness 
according to the SmPC. 
Is the event expected based on the SmPC?  It is a suspected serious 
adverse reaction. Record 
on SAE form 
It is a SUSAR 
Is the event life threatening/fatal? 
• Event must be reported to the CI within 24 
hours 
• CI reports to MHRA and MREC within 7 
days using the SAE form 
• Follow-up report within a further 8 days 
with the SAE follow-up form 
• Event must be reported 
to the CI within 24 hours 
• CI reports to MHRA and 
MREC within 15 days 
using the SAE form 
•  Follow-up report as soon 
as possible  
No 
Yes 
Yes 
Yes 
No 
No 
Adverse event observed BMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
Page 14 of 19
(page number not for citation purposes)
therapy, management of adverse drug reactions and geno-
typing. Unit costs will be sought from appropriate sources
[27,40,41].
Cost-utility analysis
For the purposes of estimating the cost-utility ratio, treat-
ment effectiveness will be assessed by eliciting utility
scores from trial participants. Patients will be asked to
complete the EQ-5D questionnaire and Visual Analogue
Scale at the time points specified. We shall also conduct a
cost-effectiveness analysis by considering the incremental
cost per depression-free week. The number of weeks free
from depression will be calculated from analysis of the
depression symptom rating scales, and by assuming linear
interpolation between time points.
Uncertainty analysis
Sensitivity analyses will be conducted to test the robust-
ness of our findings. We shall use such analyses based on
the observed distributions of outcome and costs to test
whether, and to what extent, the incremental cost-utility
and cost-effectiveness ratios are sensitive to key assump-
tions in the analysis. Uncertainty will also be addressed by
means of probabilistic sensitivity analysis with results pre-
sented as cost-effectiveness acceptability curves.
Subgroup analysis
Putative predictors of response, adverse reactions and
high cost episodes will be tested by means of generalised
linear regression models. These will be used to inform the
post-hoc analysis of the cost-effectiveness of pharmacoge-
netic testing.
Generalisability and policy implications
The findings of the economic evaluation will be compared
with the results of other health economic assessments of
antidepressant drug treatments, including the AHEAD
trial, a randomised control trial to compare the cost-effec-
tiveness of tricyclic antidepressants, selective serotonin re-
uptake inhibitors and lofepramine, funded by the HTA
programme [42]. The estimated cost per QALY (and cost
per depression-free week) of folate supplementation, and
of pharmocogenetic testing, will be compared with other
health care interventions to place into context the value
for money they may offer.
Direct access to source data/documents
Trial related monitoring, audits, Research Ethics Commit-
tee reviews and regulatory inspections will be permitted,
allowing access to data and documents where required.
Quality control and quality assurance
The conduct of this trial will follow the principles of good
clinical practice outlined by the ICH-GCP and will com-
ply with the EU directive 2001/20/EC. The research is
underpinned by the MRC guidelines for clinical trials [43-
46] and the Research Governance Frameworks for Eng-
land and Wales [47,48].
A Trial Steering Committee (TSC) will be established to
oversee the running of the trial, and will meet annually,
with the first meeting being in Month 3. A Data Monitor-
ing and Ethics sub-Committee (DMEC) will also be estab-
lished. This committee will meet independently of the
TSC but will be responsible for reporting to it.
Two other related work groups will be established to man-
age the project, a Trial Management Group (TMG) and a
Research Team (RT). The lead applicant will chair the
TMG which will meet every three months and consist of
co-applicants, collaborators, the trial co-ordinator and
service user and public involvement representatives. The
TMG will report to the TSC, and oversee the work of the
RT. The RT, chaired by the trial co-ordinator and consist-
ing of the three research professionals, will be responsible
for the day-to-day research activities. The RT will meet and
obtain input from particular members of the TMG when
relevant. Members of the TMG will also have the opportu-
nity to comment on draft questionnaires, draft papers and
any other trial material. The existing close working rela-
tionship between members of the proposed TMG will
ensure the aims and objectives of the project will be met
within the time specified.
Full ethical approval has been sought from the Multi-cen-
tre Research Ethics Committee (MREC) for Wales and
from the Local Research Ethics Committees (LRECs) at
each centre. An Eudract Number (2006-004647-37) and
clinical trial authorisation (CTA) have been received via
the Medicines and Healthcare products Regulatory
Authority (MHRA). We have ensured that there is appro-
priate insurance/indemnity to cover the liability of the
investigators. In addition, we will ensure that we obtain
written informed consent from all patients entering into
the trial and monitor, record and report any serious unex-
pected adverse reactions to the TSC and DMEC, the spon-
sor, the MHRA and ethics committees as appropriate. An
annual safety report will be provided.
Data Monitoring and Ethics Committee (DMEC)
The role of the DMEC is to consider the need for interim
analyses of trial data, the implications of such analyses,
and requests for release of interim data. It will report to
the TSC about these issues and after each meeting. As this
is a health technology assessment rather than a pharma-
ceutical trial it is less likely that the DMEC will require
interim analysis of trial data.
If two or more serious adverse events (SAEs) occur in
either of the folic acid and placebo groups, the researchBMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
Page 15 of 19
(page number not for citation purposes)
team will report this to the chair of the DMEC. The DMEC
will examine the evidence, and if there is evidence of
imbalance in SAEs between the treatment groups that
requires further action, report this to the TSC.
If new evidence becomes available during the course of
the trial, for example suggesting that folic acid is substan-
tially better or worse than no supplement, it is the respon-
sibility of the DMEC to consider such issues and make
recommendations on the continuation of the trial to the
TSC.
Ethics
MREC for Wales and appropriate LREC approval have
been sought. All trial documentation, including patient
information leaflet and consent form, referral forms and
template GP letters have been submitted for approval. To
conform to the data protection and freedom of informa-
tion acts, all data will be anonymised and stored securely.
No published material will contain patient identifying
information.
Obtaining informed consent from participants
Only patients 18 years of age or over and giving informed
consent will participate in the trial. Informed consent will
be obtained during the screening interview where both a
psychiatrist and research professional will be present to
ensure that the patient fully understands the nature of the
trial and answer any questions. Patients will also be
informed that they can withdraw from the trial at any
point and that doing so would not affect the care they
received. Patients will be given a copy of their consent
form to keep.
Patients unable to give informed consent will be excluded
from the trial.
Ethical issues of DNA testing
All genetic studies to be undertaken in the trial will be
subject to approval by a research ethics committee accred-
ited to deal with multi-domain studies. It is also impor-
tant to note that the studies will be conducted under a
strict ethical framework that adheres to guidelines devel-
oped by Department of Health, MRC and the Nuffield
Council on Bioethics. The studies will also be in accord-
ance with the Human Tissue Act [49]. The following are
the key points of the study to be undertaken, as raised by
the reviewers:
￿ The DNA samples will be transported from the site of
patient recruitment to Liverpool in a coded form where
they will be extracted and stored. The laboratory will only
know the samples by code numbers, and will not be told
of clinical details including the study arm into which the
patient has been randomised, until after all the genotyp-
ing has been completed, and the results analysed. There-
fore all genotyping will be blinded.
￿ The DNA will be stored in a coded form until the end of
the study. When the DNA has been linked to the ano-
nymised clinical details, the DNA sample will be irrevers-
ibly anonymised and the original code destroyed.
￿ All patients will be asked to take part in the genetic
study. In other genetic studies being undertaken in Liver-
pool, no patient has yet refused on the basis of the fact
that DNA was being collected. Furthermore the refusal
rate in studies involving a single blood sample for DNA
analysis is <1%. However, as the trial progresses, we will
continue to monitor the situation, and if there are prob-
lems associated with recruitment which can be related to
the genetic testing, then steps will be undertaken to rectify
the situation after consultation with the ethics committee.
All patients will be asked to give informed consent for the
genetic study. Thus additional consent, separate from con-
senting to the main study, will be required. Participants
will be asked to give specific consent to allow us to use the
participant's DNA samples to investigate the specific genes
mentioned in the protocol and broad consent to allow us
to use their anonymised samples for further genetic test-
ing. Anonymised DNA samples will be used in the future
to look at other genes relevant to responsiveness to folate,
as and when these are identified. Participants who con-
sent to the specific genetic testing will be invited to give
broad additional consent to anonymise their DNA sam-
ples for analysis conducted once the FolATED trial is com-
plete. Where no additional consent is given, the DNA
sample will be destroyed at the end of the study. The
patient information leaflet will state that these DNA sam-
ples will be considered to be a gift and will be stored
under the custodianship of University of Liverpool. No
information on the genetic analysis will be passed onto
the patients individually or to their GPs.
Data handling and record keeping
Patient information will only be accessible to the research
team. All data will be link anonymised so that no patient
identifying information will be kept with raw data. All
files will be kept with the local research teams in a locked
and secure cabinet. It is our intention however, to attempt
to make this trial as paperless as possible, thus most of the
data will be recorded electronically. Electronic data will be
stored on a central computer at each centre. Field investi-
gators will use laptops that will be cleared of data after
every visit once uploaded to the central database. The
database will be designed to ensure only valid data can be
entered. Anonymised data will be collated by NWORTH
centrally from the three participating sites on a regular
basis for ongoing analysis and quality assurance monitor-BMC Psychiatry 2007, 7:65 http://www.biomedcentral.com/1471-244X/7/65
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ing. Since NWORTH will also be coordinating the ran-
domisation procedures, the randomisation codes will be
kept on a separate database by NWORTH.
With regard to blood samples, they will be split for differ-
ent analyses depending on the consent given by the par-
ticipant. The first sample will be sent to the local
pathology laboratory for routine haematology analysis
(FBC, red cell folate, serum folate and B12), the samples
will then be destroyed. A second sample will be sent to
Cardiff for analysis of homocysteine levels, these samples
will also be destroyed following analysis. A third sample,
only taken with additional consent, will be used for DNA
analysis at the University of Liverpool and will be viewed
as a gift to the University. The samples will be stored at the
Genetic laboratory within the University with no identify-
ing information for the duration of the study. Blood sam-
ples used for genetic analyses and homocysteine will be
coded so that no patient identifying information will be
available with the sample. Blood samples used for routine
haematology will have patient details for clinical reasons
so that results can be forwarded to appropriate GPs and to
detect folate deficiency during the course of the trial. To
safeguard the research team's blindness to treatment, a
collaborating GP will monitor blood results for changes
in folate levels during the trial. We shall keep an extra
sample of the plasma at each research site as a back up for
homocysteine analysis. This is to safeguard against loss of
samples through unforeseen events like equipment fail-
ure. We shall destroy these stored samples at the end of
the study.
Anonymised electronic data will be stored by NWORTH
following the trial completion. This allows future access to
raw data. Consent forms will be stored securely at local
sites according to local research governance procedures.
All blood samples retained for genetic analysis will be
destroyed after five years unless participants give broad
consent to allow anonymised samples to be kept indefi-
nitely for future analysis. The database linking subject
identity to anonymisation codes will be stored securely at
each local site for a period of five years following the com-
pletion of the trial. This database will then be destroyed,
ensuring trial data are permanently and irreversibly ano-
nymised.
Discussion
Finance
The FolATED trial is funded by a grant from the NHS
Health Technology Assessment Programme to Bangor
University. No drug manufacturing company is sponsor-
ing the trial. Folic acid manufactures have had no involve-
ment with the design nor will they be involved with the
management or reporting of the trial. DHP Ltd are manu-
facturing the study drugs folic acid 5 mg and matching
placebo specifically for the study on a commercial basis.
This ensures that adequate objectivity with regard to the
study findings.
Cost implications
FolATED has been designed to minimise costs for partici-
pating hospitals, GPs and Community Mental Health
Teams (CMHTs). The drugs are supplied to patients free-
of-charge. Folic acid is a simple out-patient treatment and
the follow-ups scheduled for the study are only margin-
ally more than those that would be required with standard
antidepressants treatment outside the trial. To reimburse
the administration costs for GPs to refer patients to the
trial a payment of £50 will be made to GPs for each
patient recruited into the trial.
Indemnity
No special arrangements have been made for compensa-
tion for non-negligent harm suffered by patients as a
result of participating in the study. Folic acid 5 mg is
licensed for use as a treatment for folate deficiency. A
lower dose, folic acid 400 mcg is available over-the-coun-
ter as a vitamin supplement and often used by pregnant
women. The NHS indemnity liability arrangements will
apply for negligence on the part of any healthcare profes-
sional involved in the study.
Publication policy
A detailed publication strategy will be devised once the
trial has started. We are committed to publishing in as
wide afield as possible in peer reviewed journals and to
ensuring that appropriate recognition is given to anyone
who has worked on trial. We are also committed to mak-
ing research finding accessible for secondary analysis.
Conclusion
If folic acid is shown to improve the efficacy of antidepres-
sants, then it will provide a safe, simple and cheap way of
improving the treatment of depression in primary and
secondary care.
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